San Diego, CA – September 24, 2025 – Mabwell Therapeutics, a U.S.-based biotechnology company, today announced that the first patient has been dosed in a U.S. Phase II clinical study of its novel anti-TMPRSS6 antibody, MWTX-003 (also known as DISC-3405). The trial, initiated by Mabwell’s partner Disc Medicine (NASDAQ: IRON), marks a successful achievement of the Phase II study milestone in the collaboration.
The open-label, multicenter, within-participant dose-escalation study will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV). Phase I clinical results, presented at the 2025 European Hematology Association (EHA) Congress, demonstrated that DISC-3405 resulted in deep and sustained reductions in serum iron, supporting a once-monthly SC dosing regimen. It also exhibited favorable safety profile.
About MWTX-003 (DISC-3405)
In January 2023, Mabwell Therapeutics out-licensed MWTX-003 to Disc Medicine, granting Disc exclusive rights to develop, manufacture, commercialize, and otherwise exploit MWTX-003 in all territories outside of Greater China and Southeast Asia.
MWTX-003 is currently the only anti-TMPRSS6 monoclonal antibody in development for PV. Unlike exogenous hepcidin mimetics, MWTX-003 restores iron homeostasis through physiological upregulation of endogenous hepcidin expression, potentially achieving iron regulation that more closely aligns with the body’s natural biology. It has been granted Fast Track Designation (FTD) and Orphan Drug Designation (ODD) by the U.S. FDA. In parallel, three Phase 1b clinical trials are ongoing in China.
About Mabwell Therapeutics
Mabwell Therapeutics is a U.S.-based biotechnology company focused on developing innovative antibody-based therapies for serious and rare diseases. It is a wholly owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH).